jylamvo Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Jylamvo, and what generic alternatives are available?
Jylamvo is a drug marketed by Shorla and is included in one NDA. There are two patents protecting this drug.
This drug has twenty-three patent family members in eighteen countries.
The generic ingredient in JYLAMVO is methotrexate. There are twenty drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the methotrexate profile page.
DrugPatentWatch® Generic Entry Outlook for Jylamvo
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for jylamvo?
- What are the global sales for jylamvo?
- What is Average Wholesale Price for jylamvo?
Summary for jylamvo
International Patents: | 23 |
US Patents: | 2 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 137 |
Patent Applications: | 4,380 |
Drug Prices: | Drug price information for jylamvo |
What excipients (inactive ingredients) are in jylamvo? | jylamvo excipients list |
DailyMed Link: | jylamvo at DailyMed |
![jylamvo drug patent expirations Drug patent expirations by year for jylamvo](/p/graph/s/t/jylamvo-patent-expirations.png)
![Drug Prices for jylamvo](/p/graph/drug-price/jylamvo.png)
Pharmacology for jylamvo
Drug Class | Folate Analog Metabolic Inhibitor |
Mechanism of Action | Folic Acid Metabolism Inhibitors |
US Patents and Regulatory Information for jylamvo
jylamvo is protected by six US patents.
Patents protecting jylamvo
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA WITH AN ORAL SOLUTION OF METHOTREXATE
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ADULTS WITH MYCOSIS FUNGOIDES WITH AN ORAL SOLUTION OF METHOTREXATE
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMAS WITH AN ORAL SOLUTION OF METHOTREXATE
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ADULTS WITH RHEUMATOID ARTHRITIS WITH AN ORAL SOLUTION OF METHOTREXATE
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ADULTS WITH SEVERE PSORIASIS WITH AN ORAL SOLUTION OF METHOTREXATE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shorla | JYLAMVO | methotrexate | SOLUTION;ORAL | 212479-001 | Nov 29, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Shorla | JYLAMVO | methotrexate | SOLUTION;ORAL | 212479-001 | Nov 29, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for jylamvo
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Nordic Group B.V. | Nordimet | methotrexate | EMEA/H/C/003983 Nordimet is indicated for the treatment of:active rheumatoid arthritis in adult patients,polyarthritic forms of severe, active juvenile idiopathic arthritis (JIA), when the response to nonsteroidal anti-inflammatory drugs (NSAIDs) has been inadequate,moderate to severe plaque psoriasis in adults who are candidates for systemic therapy, and severe psoriatic arthritis in adult patients, induction of remission in moderate steroid-dependent Crohn's disease in adult patients, in combination with corticosteroids and for maintenance of remission, as monotherapy, in patients who have responded to methotrexate. |
Authorised | no | no | no | 2016-08-18 | |
Therakind (Europe) Limited | Jylamvo | methotrexate | EMEA/H/C/003756 In rheumatological and dermatological diseasesActive rheumatoid arthritis in adult patients.Polyarthritic forms of active, severe juvenile idiopathic arthritis (JIA) in adolescents and children aged 3 years and over when the response to non-steroidal anti-inflammatory drugs (NSAIDs) has been inadequate.Severe, treatment-refractory, disabling psoriasis which does not respond sufficiently to other forms of treatment such as phototherapy, psoralen and ultraviolet A radiation (PUVA) therapy and retinoids, and severe psoriatic arthritis in adult patients.In oncologyMaintenance treatment of acute lymphoblastic leukaemia (ALL) in adults, adolescents and children aged 3 years and over. |
Authorised | no | no | no | 2017-03-29 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for jylamvo
See the table below for patents covering jylamvo around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
China | 107106485 | 甲氨蝶呤制剂 (Methotrexate formulation) | ⤷ Sign Up |
United Kingdom | 201519049 | ⤷ Sign Up | |
Lithuania | 3212237 | ⤷ Sign Up | |
Hong Kong | 1243638 | 甲氨蝶呤製劑 (METHOTREXATE FORMULATION) | ⤷ Sign Up |
Serbia | 62971 | FORMULACIJA METOTREKSATA (METHOTREXATE FORMULATION) | ⤷ Sign Up |
Denmark | 3212237 | ⤷ Sign Up | |
Croatia | P20220105 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |